IDEX CorporationNYSE: IEX
Industrials · Industrial Machinery & Supplies & Components
$221.54
+7.75%
Vol: 34K
Research Digest
Monday, June 15, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 20IDEX raised its quarterly dividend to $0.73 and received a Buy initiation from Argus following a strong Q1 beat and raised 2026 outlook.Positive▶
IDEX Corporation held its 2026 virtual annual stockholders meeting on May 6, 2026, where shareholders backed the board, executive pay, and auditor; the company simultaneously raised its quarterly dividend to $0.73 from $0.71 per share. The dividend hike followed Q1 results reported earlier in the period with adjusted EPS of $2.00 and revenue of $886.9 million (up 8.9% YoY), prompting IDEX to lift its 2026 adjusted EPS range by $0.20 to $8.35-$8.55. Argus Research initiated coverage with a Buy rating on May 4, and Seaport Research raised its PT to $250 from $240. Additional firms including RBC Capital ($252), Baird ($257), Citi ($252), and TD Cowen ($260) raised price targets. Despite the rally, some analysts remain skeptical about organic growth and valuation, with forward P/E at 26.04.
May 19IDEX CEO Eric Ashleman exercised options for 15,385 shares at $93.27 on May 11 as analyst price targets continue to climb post-Q1 beatPositive▶
IDEX Corp continues to see positive analyst momentum following its strong Q1 2026 results, with adjusted EPS of $2.00 and revenue of $886.9M driven by Health & Science Technologies growth. Seaport Research raised its price target to $250 from $240 on May 5, while RBC Capital lifted its target to $252 from $225 on the same day. On May 11, CEO Eric D. Ashleman exercised options for 15,385 common shares at an exercise price of $93.27. The company also raised its quarterly dividend earlier in May to $0.73 from $0.71 per share. IDEX held its 2026 virtual annual stockholders meeting on May 6 with board and pay votes approved. Sentiment remains constructive though valuation concerns linger given high P/E ratios.
May 18IDEX Corp CEO Eric Ashleman exercised options for 15,385 shares on May 11 following Q1 2026 beat and raised full-year guidance to 3-4% organic growth.Positive▶
IDEX Corporation reported strong Q1 2026 results with adjusted EPS of $2.00 and revenue of $886.9M (+8.9% YoY), beating estimates with 5% organic sales growth and 10% order growth led by HST segment. The company lifted its full-year 2026 organic growth outlook to 3-4% from the prior 1-2% range. The Board raised the quarterly dividend to $0.73 from $0.71 per share on May 6. CEO Eric Ashleman exercised options for 15,385 shares at $93.27 per share on May 11, 2026. The 2026 virtual annual stockholders meeting was held May 6.
May 15IDEX CEO Eric Ashleman sold 15,385 shares on May 11 following Q1 beat, dividend hike to $0.73, and raised 2026 organic growth guidance to 3-4%.Positive▶
IDEX Corp delivered Q1 2026 adjusted EPS of $2.00 with 5% organic sales growth and 26% adjusted EBITDA margin, raising full-year organic growth guidance to 3-4%. Health & Science Technologies revenue grew 11% organically driven by data center, semiconductor, and space/defense demand. The board raised the quarterly dividend to $0.73 from $0.71 (announced May 6), and shareholders backed the board, pay, and auditor on May 8. CEO Eric Ashleman executed an insider sell of 15,385 shares on May 11. Multiple analysts raised price targets up to $260 following the strong print; risk is sustainability of HST momentum amid valuation concerns.
May 14IDEX CEO Eric Ashleman sold 15,385 shares on May 11, following a May 8 shareholder vote backing the board and a dividend hike to $0.73.Mixed▶
On May 11, 2026, IDEX Corp CEO and President Eric Ashleman executed an insider sale of 15,385 shares, the only material disclosed corporate action this week. The sale follows a May 8, 2026 annual shareholder meeting at which investors approved all board nominees, executive compensation, and ratified the auditor. Earlier in the cycle, IDEX's board lifted the quarterly cash dividend to $0.73 from $0.71. Q1 FY26 adjusted EPS came in at $2.00 (beating estimates) and management raised full-year organic sales growth guidance to 3-4%, prompting multiple analysts to lift price targets toward $260 (TD Cowen, Seaport Research, and others). Trading desks flagged the insider sale as a sentiment headwind but not a strategic shift.
May 13IDEX Corp lifted 2026 outlook after strong Q1 with adjusted EPS of $2.00 and 5% organic sales growth, driving multiple analyst price target hikesPositive▶
IDEX reported Q1 adjusted EPS of $2.00, beating estimates, with organic sales up 5% and organic orders climbing roughly 10% year over year. Health & Science Technologies led the way with organic orders up 17% and organic revenue up 11%. The company raised full-year organic sales growth guidance to 3-4%. IDEX also boosted its quarterly dividend from $0.71 to $0.73 (a 2.8% raise), marking 31 straight years of dividend growth, with ex-dividend date of May 22, 2026. Multiple analysts raised price targets including Seaport Research to $250, with Stifel, RBC Capital, Baird, and Citi also lifting targets. The favorable outlook signals continued momentum in key segments, though some valuation concerns remain.
May 12No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 11IDEX held annual meeting May 6, declared $0.73 dividend, after Q1 beat and raised 2026 organic growth outlook to 3-4%.Positive▶
On May 6, IDEX held its annual stockholder meeting where investors elected four directors to 2029 terms and ratified Deloitte as auditor. The board declared a $0.73 quarterly dividend. The actions follow strong Q1 2026 results with adjusted EPS of $2.00 and revenue of $886.9M (up 8.9% YoY). IDEX raised its full-year organic growth outlook to 3-4% from 1-2% on stronger demand. Health & Science Technologies was the standout with organic orders up 17% and revenue up 11%, helped by data center, semiconductor, space/defense and pharma demand. Risk: high valuation and some softness in industrial/life sciences end markets.
May 8Q1 revenue $886.9M beats est, adjusted EPS $2.00, organic growth raised to 3%-4%, HST strongPositive▶
IDEX reported strong Q1 2026 revenue of $886.9 million and adjusted EPS of $2.00, both exceeding estimates. Company lifted full-year 2026 organic growth outlook to 3%-4% from prior 1%-2% range. Delivered 5% organic sales growth and 10% order growth in Q1. Health & Science Technologies segment standout with 17% organic orders growth and 11% organic revenue growth. Adjusted EBITDA margin of 26% with 50 bps YoY expansion. Board approved regular quarterly cash dividend of $0.73 per share.
May 7Q1 EPS $2.00 beats; record orders $988.3M +13%; HST revenue +11% organic; raised FY2026 organic growth to 3-4%Positive▶
IDEX reported Q1 2026 EPS of $2.00, beating $1.77 estimate, with revenue of $887M exceeding $846M forecast. Orders reached record $988.3M, up 13% reported and 10% organically. Health & Science Technologies segment led with organic revenue growth of 11% and organic orders growth of 17%, driven by data center, semiconductor, space, defense, and pharma demand. Company raised FY2026 organic growth outlook to 3-4% (from prior 1-2%), maintaining adjusted EBITDA margin guidance at 26.5-27.0% and raising adjusted EPS to $8.35-$8.55. Sean Gillen appointed CFO effective Jan 5, 2026. Board approved regular quarterly dividend of $0.73/share. Analyst consensus: Strong Buy with PT $234.89 (+8.87%).
May 6IDEX reports strong Q1 results with raised full-year guidancePositive▶
IDEX Corporation delivered strong first quarter 2026 results on April 29, with revenue of $886.9 million and adjusted EPS of $2.00, both exceeding estimates. The company reported 5% organic sales growth and raised its full-year guidance, driven by momentum in the Health & Science Technologies segment. Fourth quarter 2025 saw record sales of $899 million and record orders of $979 million. The company achieved continued success through acquisitions including Micro-LAM, Inc. in July 2025 and Airshore International. Stifel analyst activity included a price target reduction from $244 to $241 on April 14, 2026.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| IEXIDEX | $221.54 | +7.75% | -1.4% | 22.3x | 1.01 | $15.2B |
| PHPARKER | $929.61 | +7.50% | +0.7% | 25.4x | 1.18 | $109.0B |
| ITWILLINOIS | $261.80 | +4.75% | +0.2% | 20.5x | 1.05 | $71.9B |
| GWWWW | $1,317.46 | +6.31% | -2.0% | 24.6x | 1.04 | $58.5B |
| DOVDOVER | $222.33 | +7.01% | -1.4% | 17.9x | 1.21 | $28.0B |
| IRINGERSOLL | $77.46 | +10.22% | +0.4% | 18.3x | 1.25 | $27.5B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.